A long-standing mystery in the cardiovascular field is the developmental origin of coronary arteries. [1] [2] [3] [4] There is consensus that coronary veins arise from the venous endothelium of the sinus venosus (SV; the common vein through which blood passes before entry into the right atrium), which sends nascent sprouts to the heart that assemble into a subepicardial plexus before further maturation. Coronary veins remain in a subepicardial location on the heart surface. Studies of the origin of coronary arterial endothelium implicated 2 major candidate sources: ventricular endocardium (VE) and SV, but there is ongoing controversy over their relative contribution. 2, [5] [6] [7] [8] [9] [10] [11] Resolving this issue is important because these 2 proposed origins represent 2 completely different development mechanisms for coronary vessel formation. An SV source implies that both models are involved in coronary arterial formation; however, quantification by different groups reached vastly different estimates of the relative contribution of these 2 sources. 5, [7] [8] [9] [10] 12 This discrepancy engenders an urgent need for resolution of this controversial issue, not only to reveal the developmental sources of the coronary endothelium, but also more importantly to unravel the distinct developmental mechanisms responsible for coronary vessel formation and to aid in designing new strategies for therapeutic cardiac revascularization.
A recent study used nuclear factor of activated T cells (Nfatc1)-Cre lineage tracing to show that Nfatc1-derived cells constitute the majority of coronary arteries in the developing heart. 7 In this study, Nfatc1-Cre was asserted to recombine in VE but not in SV endothelium, and therefore, these data were interpreted to conclude that the VE, but not the SV, gives rise to most coronary arteries. However, the extent to which Nfatc1-Cre labels the SV was not fully investigated in that study. Furthermore, ectopic expression of Nfatc1 in coronary vessels might undermine the interpretation of those results, which were based on a constitutively active Cre line. 13 The major conclusion of the Wu et al study contradicts an earlier clonal analysis that implicated the SV as the major source for coronary arteries. 5 In addition, a recent lineage tracing based on Apln-CreER showed that subepicardial vessels invade myocardium to generate most coronary arteries in ventricular free walls, 8 and recent molecular studies of coronary vessel formation also support the SV as the primary origin for coronary arteries in the embryonic ventricular free walls. 14 These observations challenge the VE as the origin of most coronary arteries in the developing heart. However, direct evidence to either support or refute this conclusion has been lacking. Here, we generated new mouse genetic tools and revisited this controversial question with fate mapping and intersectional lineage tracing studies. Our analysis demonstrated that ventricle endocardium minimally contributes to coronary endothelium in the embryonic ventricular free walls (model 2, Online Figure IA) , suggesting that the SV is the major source of coronary endothelium in the developing heart (model 1, Online Figure IA ).
Methods
Detailed Materials and Methods are provided in the Online Data Supplement. All animal protocols were approved by the Institutional Animal Care and Use Committee at the Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Science. Immunostaining and in situ hybridization were performed according to protocol described previously. 15 The
Nfatc1-Cre, Nfatc1-Dre, Nfatc1-GFP, natriuretic peptide receptor 3 (Npr3)-CreER, and Npr3-GFP mouse lines were generated by Shanghai Biomodel Organism Co, Ltd. All data were collected from at least 3 independent experiments as indicated and were presented as mean values±SEM. Statistical comparisons between data sets were done by a 2-side unpaired Student's t test for comparing differences between 2 groups. P<0.05 was considered to be statistically significant.
Results

Nfatc1 Constitutive Recombinases Label Both VE and SV
To evaluate the lineage and fate of Nfatc1 + cells, we first generated Nfatc1-Cre by knockin of IRES-Cre into the Nfatc1 3' untranslated region ( Figure 1A ), which targets exactly the same gene location as the mouse line reported previously. 7 We crossed Nfatc1-Cre with reporter line R26-tdTomato to permanently label Nfatc1-expressing cells and their descendants ( Figure 1B) . We collected E9.5 to E15.5 Nfatc1-Cre;R26-tdTomato embryos ( Figure 1C ) and performed immunostaining for genetic lineage marker tdTomato and endothelial cell (EC) marker VE-cadherin (CDH5). The tdTomato + cells, derived from the Nfatc1 + precursors, are detected in most SV ECs as well as VE at E9.5 and E11.5 ( Figure 1D and 1E). By staining for coronary EC-specific marker fatty acid binding protein 4 (FABP4), we found that Nfatc1-derived cells (tdTomato + ) contribute to the majority of FABP4 + subepicardial ECs as well as intramyocardial coronary vessels in E13.5 and E15.5 embryonic heart (Figure 1F and 1G; Online Figure IB and IC). These data demonstrated that Nfatc1-Cre line labels SV notably, in addition to VE in the developing heart.
To confirm the above lineage tracing data, we generated another recombinase line, Nfatc1-Dre, for lineage tracing of Nfatc1 + cells. 15 We crossed Nfatc1-Dre with its specific reporter line Rosa26-Rox-Stop-Rox-tdTomato (R26-RSR-tdTomato) to perform lineage tracing of Nfatc1 + cells in the developing heart (Figure 2A ). In E10.5 and E11.5 Nfatc1-Dre;R26-RSR-tdTomato hearts, we found that Nfatc1-Dre labels SV cells as well as ventricular endocardial cells ( Figure 2B-2D ). Nfatc1-derived cells contribute to subepicardial ECs at E12.5 ( Figure 2E ) and to the majority of intramyocardial coronary ECs at E15.5 ( Figure 2F ). Quantification of the number of labeled subepicardial vessels and intramyocardial vessels at E15.5 showed that there was no significant difference in the labeling efficiency of these 2 populations ( Figure 2G ). These data suggest that Nfatc1 + cells contribute equally to subepicardial vessels and intramyocardial arteries. Immunostaining for the arterial endothelial marker connexin 40 confirmed that coronary arteries in the ventricular free walls of the embryonic heart express the Nfatc1 lineage marker ( Figure 2H ). In sum, our Nfatc1 recombinase lines consistently showed that Nfatc1 + cells constitute the SV in addition to the VE. Because both Nfatc1-Cre and -Dre efficiently label the SV, the interpretation of the observation that the coronary arteries are Nfatc1-derived cannot be attributed to only a VE source.
Nfatc1 Is Expressed in the SV and Coronary Vessels
We next studied the reason why Nfatc1-Dre labels the SV because previous work implied that Nfatc1 mRNA and protein are not expressed in the SV. 7 It should be noted that this negative expression was based on observations of E9.5 and E10.5 embryos. 7 Because Nfatc1 constitutive Cre was used for fate mapping, it is critical to examine other time points to fully exclude the possibility of unrecognized Nfatc1 expression. To examine Nfatc1 expression at earlier time point (eg, E8.0-E8.5), we used an Nfatc1-GFP knockin mouse line, in which the Nfatc1 coding region is followed by GFP with a 2A linking peptide. By whole-mount immunostaining of GFP as a surrogate for Nfatc1 expression, we detected GFP expression in the 2 horns of the SV at E8.0 to E8.5 (Online Figure  IIA) . In sections, it was evident that Nfatc1 (as visualized by + myocardium in the early developing heart (Online Figure IIB) . Therefore, labeling of the SV by Nfatc1-Dre as a lineage marker (Figure 2 ) can be explained by early embryonic Nfatc1 gene expression in the SV. Nfatc1 expression is known to be downregulated in VE at later time points after E11.5. 7, 16 To further examine Nfatc1 expression in coronary endothelium at later time points, we collected E15.5 Nfatc1-GFP heart sections and immunostained for GFP and the pan-endothelial marker CDH5 (VE-cadherin). We found that a subset of coronary ECs, in both subepicardial and intramyocardial locations, was GFP positive (Online Figure IIC) . Using NFATC1 antibody staining on E15.5 wild-type heart sections, we similarly found NFATC1-expressing coronary vascular ECs (Online Figure IID) . These observations indicate continuing albeit perhaps sporadic Nfatc1 expression in coronary endothelium and are consistent with a previous report showing Nfatc1 in midgestation coronary vessels. 13 To independently confirm Nfatc1 expression in coronary vasculature, we isolated E14.5 coronary ECs by fluorescence-activated cell sorting from Apln-CreER;Rosa26-mTmG mice that were treated with tamoxifen at E10.5. 8 Apln is a specific marker for vascular ECs and is not expressed in endocardium. 5, 17 As a positive control, we isolated endocardial and vascular ECs as a single combined population from Tie2-GFP mouse hearts, and as a negative control, we isolated cardiomyocytes from Tnt-Cre;Rosa26-mTmG mice. Reverse transcription polymerase chain reaction analysis by 2 different sets of Nfatc1 primers showed expression of Nfatc1 in coronary vascular ECs (Online Figure IIE) . Altogether, these data provide several candidate reasons why Nfatc1-Cre or Nfatc1-Dre labels coronary vessels-expression in the E8.5 SV, expression in the E9.5 to 10.5 VE, and expression in at least some coronary endothelium at E14.5 to E15.5. The previous interpretation that Nfatc1-Cre recombination is restricted to the endocardium, and therefore that VE contributes to the majority of coronary arteries, clearly requires further analysis by more restricted genetic lineage tools.
Identification and Characterization of Npr3 as a New Endocardial Marker
To find a marker that is more exclusively expressed in endocardium but not coronary ECs, we dissociated cells from E14.5 hearts, sorted cardiomyocytes, pan-ECs (including both endocardium and coronary endothelium) and smooth muscle cells by flow cytometry, and performed single-cell gene expression analysis using the Fluidigm platform. We could clearly distinguish these 3 main types of cardiovascular cells by gene expression signatures ( Figure 3A ). All ECs expressed the pan-endothelial markers platelet/endothelial cell adhesion molecule 1 (Pecam) and Cdh5. Importantly, we were able to divide the EC population into 2 subgroups based on expression of Fabp4, which is expressed in vascular ECs but not in endocardium. 18, 19 This analysis confirmed weak expression of Nfatc1 in both Fabp4 + and Fabp4 − populations, consistent with our immunostaining and reverse transcription polymerase chain reaction data (Online Figure IIC-IIE) and supporting the interpretation that Nfatc1 is expressed in some coronary ECs at E14.5 to E15.5.
This analysis also revealed that a gene Npr3 was expressed in the EC population in a mutually exclusive manner with Fabp4 ( Figure 3A ) and thus might represent an endocardium-specific marker. Whole mount and section in situ hybridization showed that Npr3 was highly enriched in atrial endocardium and VE, but undetectable in SV ( Figure 3B ). To specifically co-stain Npr3 + cells with other lineage-specific markers, we generated the reporter mouse line Npr3-GFP, in which a GFPCre fusion cDNA was knocked into the 3′ untranslated region of the Npr3 gene by homologous recombination ( Figure 3C ). We stained Npr3-GFP heart sections with GFP antibody as a surrogate for Npr3 expression and found that Npr3 was expressed in atrial endocardium and VE but not in the SV in E10.5 hearts ( Figure 3D ). At E12.5 and E14.5, Npr3 is expressed in endocardium but not in coronary vascular ECs in the compact myocardium ( Figure 3E and 3F). These data indicate that the newly identified endocardial gene Npr3 is not expressed in SV or coronary vessels.
For fate mapping approaches, it was important to confirm that Npr3 is co-expressed with Nfatc1 in endocardial cells in the early developing heart. Because Nfatc1 is reduced in expression after E9.5, we used Nfatc1-Dre;R26-RSR-tdTomato to mark Nfatc1 + cells and their derivatives. The rox-Stoprox reporter is a substrate only for Dre recombinase and is not recognized by Cre recombinase. 20 By generating Npr3-CreER;Nfatc1-Dre;R26-RSR-tdTomato mice, we could take advantage of the Dre-Rox system to mark Nfatc1 + cells and used estrogen receptor (ESR) antibody to detect CreER as a surrogate for Npr3 expression. Immunostaining for ESR, tdTomato, and CDH5 on E9.5 and E10.5 embryonic heart sections showed that Npr3-CreER is expressed in almost all Nfatc1 + endocardial cells ( Figure 4A and 4B). Altogether, the above data based on in situ hybridization, immunostaining, and single-cell quantitative polymerase chain reaction analysis prove Npr3 as a specific endocardial cell marker.
Npr3-CreER Labels VE but Not SV
Nfatc1-Cre or Nfatc1-Dre labels both VE and SV in the early heart, and Nfatc1 is expressed in a subset of coronary vascular ECs in E14.5 to E15.5 hearts, which compromise the utility of Nfatc1 as a lineage marker informative for the origins of coronary endothelium. We tested whether Npr3-CreER could label the endocardium in a more specific manner. By immunostaining for ESR and GFP on E8.5 Npr3-CreER and Npr3-GFP embryonic sections, respectively, we found Npr3 was expressed in atrium and VE but not SV (Online Figure IIIA and IIIB). We next collected Npr3-CreER embryos from E9.5 to E11.5; immunostaining against ESR showed that Npr3 was expressed in atrial endocardium and VE, but not in the SV at E9.5, E10.5, and E11.5 ( Figure 5A-5C ). In addition, Npr3 was also expressed in the ECs of the dorsal aorta at E9.5 and E10.5 ( Figure 5A and 5B, arrowheads) and a subset of nonendothelial mesenchymal cells at E11.5 ( Figure 5C , arrowheads). We also noticed that Npr3 was expressed in a subset of TBX18 study because it provides an opportunity to distinguish VEderived coronary vessels from SV-derived coronary vessels. Based on this unique expression profile, we performed fate mapping analysis of Npr3-CreER;R26-tdTomato by tamoxifen injection at E8.5. We collected E10.5 and E11.5 embryos for examination of VE, SV, and the earliest coronary vessels in the atrioventricular groove. The E10.5 heart has no coronary ECs in the atrioventricular groove or in the compact myocardium, and 73.13±6.53% VE cells were labeled, whereas SV cells were not labeled ( Figure 5D ). The E11.5 heart shows the first coronary vessels appearing in the atrioventricular groove ( Figure 5E ). The 78.33±2.89% VE cells were labeled, whereas the SV and coronary ECs that are in the process of sprouting from the SV to the atrioventricular groove were not labeled ( Figure 5E ). These data show that Npr3 is expressed in VE but not in SV endothelium and that Npr3-CreER labels the VE but not SV in the E10.5 to E11.5 developing heart ( Figure 5F ).
Npr3 + VE Minimally Contributes to Coronary Vessels in Ventricular Free Walls
We next collected hearts at later embryonic stage to quantitatively measure the contribution of Npr3-CreER-labeled VE to coronary ECs. We labeled Npr3 + VE by tamoxifen induction at E8.5 and checked the coronary vessels in the compact myocardium of E12.5 to E15.5 hearts. Immunostaining for tdTomato and PECAM on E12.5 hearts showed that tdTomato + PECAM + ECs constitute 4.56±2.20% of subepicardial coronary vessels in the ventricular wall ( Figure 6A ). We also found that 80.21±14.21% endocardial cells are labeled in the same hearts ( Figure 6A ). Npr3-CreER also labels atrial endocardial cells, and there was almost no coronary vessels detected in the atrial free wall at this stage (Online Figure VI) . We next collected E14.5 Npr3-CreER;R26-tdTomato hearts and detected tdTomato signal enriched in the core of the heart, with almost no signal in the ventricular free walls ( Figure 6B ).
Immunostaining for tdTomato and PECAM on E14.5 heart sections showed that although most VE cells are labeled, only a few coronary ECs in the ventricular free walls are tdTomato positive ( Figure 6C and 6D) . Because of sectional orientation and the deep ingression of some trabecular lacunae into the compact zone, some of the PECAM + endocardium is ambiguous in morphology from coronary vascular ECs, possibly causing some VE cells to be mistakenly interpreted as coronary vessels. To avoid this possible caveat in coronary vessel quantification, we used the coronary vascular endothelial-specific marker FABP4. 18, 19 We co-stained FABP4 with tdTomato on E14.5 Npr3-CreER;R26-tdTomato embryos and found that tdTomato + FABP4
+ coronary vessels constitute the minority of Figure 6E and 6F). Immunostaining on serial sections across the heart showed that Npr3 + VE cells contribute to few coronary vessels in most parts of the ventricular free walls (Online Figure VII) . Quantification of the number of labeled coronary vessels showed that although Npr3-CreER robustly labels ventricular endocardium, it labels significantly fewer coronary vessels in the right and left ventricle wall ( Figure 6G ). However, we did find that Npr3 + VE cells contribute to a substantial amount of coronary vessels in the ventricular septum and the most ventral part of ventricular free wall connecting to the ventricular septum (last row, Online Figure VIIB) . Immunostaining for tdTomato and FABP4 on E15.5 Npr3-CreER;R26-tdTomato hearts confirmed that VE cells minimally contribute to coronary vessels in the ventricular free wall, but amply to coronary vessels in the septum (88.75±4.84% in ventricular septum, Online Figure VIII) . These results therefore suggested that ventricular endocardial cells minimally contribute to coronary vessels in the embryonic ventricular free wall. 21 we established a strategy that labels the Nfatc1 + VE only and dis-labels (subtracts labeling of) Nfatc1 + SV. 22 Dre and Cre are 2 types of recombinases that exclusively target their own recombination sites Rox and LoxP, respectively (Online Figure IXA) . We validated that Cre does not recombine Rox sequences, and Dre does not recombine LoxP sites (Online Figure IXA) . In the Ai66 reporter line, only cells expressing both Cre and Dre (and their descendants) are labeled by tdTomato (Online Figure IXB and IXC) . In E10.5 and E11.5 Nfatc1-Dre;Npr3-CreER;Ai66 hearts after tamoxifen injection at E8.5, the Nfatc1 +
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+ VE was labeled, whereas the Nfatc1 + Npr3 -SV was not ( Figure 7A and 7B) . In a side-by-side comparison of Nfatc1-Dre alone with Nfatc1-Dre;Npr3-CreER embryos, we found that dis-labeling of the SV from the Nfatc1 + domain dramatically reduced the labeling of both intramyocardial and subepicardial coronary vessels in E13.5 and E15.5 hearts ( Figure 7C and 7D) . Quantification of labeled coronary ECs in the ventricular free walls showed that Nfatc1 + cells (VE+SV cells) contributed to 77.81±5.62% coronary vessels, whereas Nfatc1 + Npr3
+ VE cells contributed to 3.13±0.72% coronary vessels. These results are consistent with an SV origin of endothelium forming the coronary system. 5 Our study reinterprets the contribution of Nfatc1 + endocardial cells to coronary vessels in ventricular free walls and indicates that labeling of the SV rather than the VE by Nfatc1-Cre in the previous study 7 could be a better explanation for the origins of the coronary endothelium in the embryonic ventricular free walls.
Identification of Other Markers for Endocardium or Coronary Endothelium
Endocardial cells and coronary ECs are 2 distinctive types of ECs with different molecular profiles: endocardial cells express relatively high level of Nfatc1, Npr3, whereas coronary ECs express high level of Apln and Fabp4. 5, 7, 19 To provide the genomewide information of their distinct gene expression profiles, we took advantage of Npr3-CreER and Fabp4-Cre lines to label enriched population of endocardium and coronary endothelium, respectively. We generated Npr3-CreER;Ai47 (GFP reporter line) and labeled endocardial cells by tamoxifen injection at E10.5. Immunostaining for GFP showed most GFP + cells are restricted to endocardial cells in E14.5 heart ( Figure 8A ). We generated Fabp4-CreER;Ai47 mice, in which coronary ECs were labeled by GFP at E14.5 ( Figure 8D ). We isolated the GFP + cells and GFP − cells from Npr3-CreER;Ai47 or Fabp4-Cre;Ai47 ventricles by flow cytometry and collected RNA from purified cells for gene analysis (Figure 8B and 8E) . Quantitative reverse transcription polymerase chain reaction of conventional pan-EC markers Pecam, Cdh5, and Flk1 showed that these genes were highly enriched in GFP + populations compared with GFP − populations ( Figure 8C and 8F) , confirming the isolation of ECs in high purity. We next performed RNA sequencing on endocardium-enriched and coronary endothelium-enriched populations and compared the differentiated gene expression between 2 GFP + populations ( Figure 8G ; Online Table I ). In addition to Npr3 and Fabp4 that were highly enriched in endocardium or coronary endothelium samples, respectively, we identified additional genes that are significantly higher in expression in either endocardium or coronary endothelium. For instance, the expression of Gpr126, Hapln1, Col23a1, and so on are significantly higher in endocardium samples, whereas the expression of Aoc3, Gpihbp1, Sema7a, and so on were significantly higher in coronary endothelium samples ( Figure 8H) . Altogether, the information on new molecular markers for endocardium or coronary endothelium would be valuable for the future study in cardiovascular research field.
Discussion
The main findings of this study are that (1) in addition to VE, Nfatc1-Cre or Dre labels both SV and subepicardial coronary vessels; (2) the newly identified marker Npr3 is co-expressed with Nfatc1 in VE, but is not expressed in the SV; (3) VE contributes to only a small minority of coronary vessels in ventricular free walls of embryonic hearts; (4) the Nfatc1 + Nrp3 -SV is likely the major source of coronary vasculature in ventricular free walls; and (5) we provide information of new molecular markers specific for endocardium or coronary endothelium.
Determining the origin of coronary arteries is pivotal to further understanding the developmental program of coronary vessel formation and provides new insights to potential new treatments to coronary artery diseases. Many studies and reviews in the past years have made valuable contributions to the ongoing debate on the origins of coronary vessels in the developing heart. [5] [6] [7] [8] 14, [23] [24] [25] [26] [27] A consensus has emerged that there are 3 important sources for coronary vessels: proepicardium, VE, and SV. [1] [2] [3] [4] 28 Each source represents a unique developmental origin that may determine different models of coronary vessels formation. However, there is controversy over whether VE or SV is the major source for most coronary vessels. Wu's study concluded that ventricular endocardial cells invade the compact myocardium to form the majority of intramyocardial coronary vessels, whereas other previous studies suggested that subepicardial vessels originally from the SV invade the compact myocardium to form the majority of coronary vessels. The 2 different tissue origins thus lead to two inverse models of coronary vessel formation in the compact myocardium. By Nfatc1-Cre lineage tracing, Wu et al interpreted that the majority of coronary arteries in the ventricular free walls were from VE. However, this conclusion is not substantiated because Nfatc1-Cre also labels the SV extensively. We confirmed that Nfatc1 constitutive recombinase labeled both VE and SV efficiently. Our study showed that Nfatc1 was expressed in the SV of E8.0 to E8.5 embryos, which explains why the SV is labeled by Nfatc1-Cre or Nfatc1-Dre at later stages even when the Nfatc1 gene itself is no longer expressed. In addition, interpretation of Nfatc1-Cre lineage tracing hinges on an absence of Cre expression in coronary vascular ECs. We found that Nfatc1 was expressed in coronary vascular ECs, in agreement with previous report. 13 Such that recombinase expression, even in a trace amount that is hard for detection, in coronary vascular ECs might genetically label vessels in situ. Although we could not infer from this expression data whether Nfatc1-Cre recombination events do take place in mature ECs, it is more cautious to perform inducible lineage tracing, such as with CreERT2, to label candidate precursor cells before coronary vessels start to form.
In this study, we also identified a new endocardial gene, Npr3, which is specifically expressed in VE but not SV. Taking advantage of this unique expression pattern, we performed lineage tracing based on Npr3-CreER tools. Npr3-CreER distinguishes VE from SV, thus eliminating the confounding labeling issue associated with Nfatc1-Cre. Npr3 is expressed in almost all Nfatc1 + ventricular endocardial cells, and the genetic labeling of VE by Npr3-CreER is efficient in our study for subsequent analysis. Our lineage tracing data showed that only a minority of coronary vessels is derived from Npr3-CreERlabeled VE cells. As an internal control, we did find that Npr3-CreER-labeled VE cells contribute to the majority of coronary vessels in the interventricular septum, suggesting that Npr3-CreER-labeled VE cells do contribute to coronary vessels (septal vessels), but in a specific compartment of developing heart. 5 Although the VE alone minimally contributes to coronary vessels in ventricular free walls, the VE and SV together (ie, the Nfatc1 + lineage) contribute to the majority of coronary vessels (Figures 1 and 2) . By using a dual recombinase-based intersectional lineage tracing strategy, we could subtract the SV from the Nfatc1 + recombination domain and compare its fate with that of labeled Nfatc1 + SV. However, direct demonstration of coronary vessel formation from SV ECs requires usage of an inducible Cre line that specifically label SV but not endocardial cells, such as Apj-CreER. 10 Interestingly, we also found that Npr3 is expressed in a minority of epicardial cells but not proepicardial cells. Proepicardium/epicardium has been reported to contribute to a substantial number of coronary vascular ECs in chicken model. 24 However, Cre-based lineage tracing in mouse studies showed that at most a small fraction of coronary vascular ECs arise from (pro)epicardium. 6, [28] [29] [30] [31] [32] In this study, although a few epicardial cells were labeled by Npr3-CreER, Npr3 + cells (including Npr3 + epicardial cells) minimally contributed to coronary vessels in the ventricular free walls. Taken together, our data are consistent with previous work suggesting the SV as the major source for coronary vessels in the ventricular free walls. 5 In addition to concluding a VE source for coronary arterial endothelium, Wu et al also noted a requirement for vascular endothelial growth factor A (VEGF) signaling in coronary arteriogenesis (VEGFR2 deletion by Nfatc1-Cre) and interpreted this requirement as a specific program associated with coronary artery formation from the VE. Because our study suggests that the majority of the coronary endothelium in ventricular free walls is derived from the SV, the role of VEGF signaling in this process must be reconsidered. Coronary ECs from the SV migrate to the atrioventricular groove and form an immature subepicardial vascular plexus over the ventricular surface during the E11.5 to 13.5 period. A maturation process then results in the differentiation of this plexus into arteries and veins.
14 Plexus maturation and arterial differentiation are both dependent on VEGF signaling, which explains the requirement for myocardial-endothelial VEGF signaling observed by Wu et al.
It remains intriguing why 2 different coronary developmental programs coexist, originating from 2 distinct sources with inverse distribution in the developing heart. Our data suggest that sprouting from the SV is the primary program that supports early coronary vasculogenesis. The SV is located on the dorsal side of the heart facing the atrioventricular groove, and from the atrioventricular groove, SV-derived ECs form a vascular plexus over the surface of the ventricle in a dorsal to ventral direction. This plexus then differentiates into the coronary arteries and veins in the ventricular walls. Because the ventricular septum facing the ventral side of the heart is the most distant to the origin of these coronary endothelium, this part might otherwise remain undervascularized. Compaction of trabecular myocardium into the ventricular septum and conversion of VE to coronary endothelium might therefore have arisen as an alternate way to initiate coronary perfusion through the septum. 8, 10 A similar program of trabecular compaction associated with conversion of VE to coronary endothelium seems to also occur in the ventricular free wall at perinatal stage. 9 Taken together, our study suggests that 2 different programs, each based on a different embryonic lineage origin, form the coronary vascular network in different compartments of the developing heart. 12 Derivation from the SV is the major source of both arterial and venous coronary vascular ECs in the embryonic ventricular free walls.
What Is Known?
• Coronary endothelial cells have multiple developmental origins.
• Sinus venosus and ventricular endocardium are considered 2 principal sources.
• Ventricular endocardium is reported to contribute to the majority of coronary arteries in embryonic ventricular free walls.
What New Information Does This Article Contribute?
• NFATC1 is expressed in sinus venosus endothelial cells at early embryonic stages.
• Ventricular endocardium minimally contributes to coronary vessels in embryonic ventricular free walls. • Nfatc1-Cre genetic tagging identifies sinus venosus as a major source of coronary vessels in embryonic ventricular free walls.
Coronary artery disease causes myocardial infarction and heart failure, making it the leading cause of death worldwide.
Understanding the developmental origin of coronary artery formation could inspire novel regenerative treatments for cardiac diseases. However, the developmental origin(s) of coronary arteries has been debated for several decades. Previous studies have identified endocardium as a major source of coronary arteries in the embryonic heart and have shown separate origin of coronary arteries and veins in the mouse heart. The findings of the present study show that endocardium is not the major source for coronary vessels in the embryonic ventricular free walls. Instead, sinus venosus contributes to the majority of coronary vessels (arteries and veins alike) in ventricular free walls. The findings could help to resolve the recent controversy over the developmental origin(s) of coronary arteries in embryonic ventricular free walls, providing the basis for studying coronary vessel formation and regeneration after injury. previously. [1] [2] [3] [4] [5] [6] The R26-RSR-tdTomato mouse line was generated by crossing Ai66 mouse with ACTB-Cre, 7 which removed the transcriptional stop cassette flanked by two LoxP sites. Nfatc1-Cre knock-in mouse line was generated by targeting exactly the same genomic locus of Nfatc1 as described previously. 8 Briefly, Nfatc1-Cre mouse line was generated by homologous recombination using Red/ET recombineering, 9 and the knock- Npr3-GFP mouse lines were generated by Shanghai Biomodel Organism Co., Ltd.
Supplemental Materials Endocardium Minimally Contributes to Coronary Endothelium in the Embryonic
Genomic DNA for genotyping was prepared from embryonic yolk sac or mouse tail.
Tissues were lysed by incubation with Proteinase K overnight at 55°C. DNA was precipitated by adding isopropanol, and washed in 70% ethanol. Detailed information for genotyping primers for each mouse line could be provided upon request.
Immunofluorescent Staining
We performed immunostaining according to the previous protocols. 11 Briefly, embryos or embryonic hearts from timed pregnant mice were collected and washed in PBS, and then 
Single Cell Preparation and Real-time PCR Analysis
Single cell preparation and analysis were performed as described previously. 15 Mouse embryos were harvested from pregnant CD1 female mice at 14. 
RNA-sequencing Preparation and Real-time qPCR Analysis
For isolating endocardial cells, tamoxifen was administrated to Npr3-CreER;Ai47 at E10.5 and embryonic hearts were collected at E14.5. For isolating coronary endothelial cells, hearts were harvested from Fabp4-Cre;Ai47 at E14.5. Ventricles were then minced with fine scissors. After digestion in lysis buffer containing collagenase, trypsin and DNase I, supernatant was collected and filtered through a 70 µm disposable cell strainer.
Then isolated cells were pelleted and re-suspended in PBS, which are ready for sorting by FACS (BDAria IIu Cytometer). After GFP positive cells were isolated by flow cytometry, RNA was extracted with Trizol according to the manufacturer's instruction (Invitrogen).
RNA-sequencing and analysis were carried out by Beijing Genomics Institute (BGI). We converted the RNA to cDNA using Prime Script RT kit (Takara). SYBR Green qPCR master mix (Applied Biosystems) was used and cDNA was amplified on a
StepOnePlus TM real-time PCR system (Applied Biosystems). Detailed information for qRT-PCR primers could be provided upon request.
Whole Mount X-gal Staining
Whole mount x-gal staining was performed as protocols described previously. 17 Briefly, embryos from timed pregnancies were fixed in 2% PFA and 0.2% glutaraldehyde in PBS 
Statistical Analysis
All data were collected from at least 3 independent experiments as indicated. For analysis of contribution of endocardial cells to coronary endothelial cells, we collected four heart samples for each experiment. 10 tissue sections from each heart were collected, and 4 fields in each section were taken images for analysis. The labeling percentage was then calculated as tdTomato + PECAM/CDH5 + cells in total PECAM/CDH5 + endothelial cells.
Quantification was performed by a lab member who was blinded to the sample identification. Data were presented as mean values ± s.e.m. Statistical comparisons between data sets were done by a two-side unpaired Student's t test for comparing differences between two groups. P < 0.05 was considered to be statistically significant.
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